Search

The locus coeruleus‐norepinephrine (LC‐NE) system, which regulates arousal levels, is important for cognitive control, including emotional conflict resolution. Additionally, the LC‐NE system is implicated in P300 generation. If the P300 is mediated by the LC‐NE system, and considering the established correlations between LC activity and pupil dilation, P300 amplitude should correlate with task‐evoked (phasic) pupil dilation on a trial‐by‐trial basis. However, prior studies, predominantly utilizing oddball‐type paradigms, have not demonstrated correlations between concurrently recorded task‐evoked pupil dilation and P300 responses. Using a recently developed emotional face‐word Stroop task that links pupil dilation to the LC‐NE system, here, we examined both intra‐ and inter‐individual correlations between task‐evoked pupil dilation and P300 amplitude. We found that lower accuracy, slower reaction times, and larger task‐evoked pupil dilation were obtained in the incongruent compared to the congruent condition. Furthermore, we observed intra‐individual correlations between task‐evoked pupil dilation and P300 amplitude, with larger pupil dilation correlating with a greater P300 amplitude. In contrast, pupil dilation did not exhibit consistent correlations with N450 and N170 amplitudes. Baseline (tonic) pupil size also showed correlations with P300 and N170 amplitudes, with smaller pupil size corresponding to larger amplitude. Moreover, inter‐individual differences in task‐evoked pupil dilation between the congruent and incongruent conditions correlated with differences in reaction time and P300 amplitude, though these effects only approached significance. To summarize, our study provides evidence for a connection between task‐evoked pupil dilation and P300 amplitude at the single‐trial level, suggesting the involvement of the LC‐NE system in P300 generation. The locus coeruleus‐norepinephrine system is implicated in the generation of the P300. Using pupillometry as an indirect measure of locus coeruleus‐norepinephrine activity, we demonstrated intra‐individual trial‐to‐trial correlations between concurrently recorded task‐evoked pupil dilation and P300 responses in the emotional face‐word Stroop task, with larger pupil dilation correlating with a greater P300 amplitude, suggesting the involvement of the locus coeruleus‐norepinephrine system in P300 generation. [ABSTRACT FROM AUTHOR]

This work describes the preparation of a PEGylated niosomes-mediated drug delivery systems for Paeonol, thereby improving the bioavailability and chemical stability of Paeonol, prolonging its cellular uptake and enhancing its synergistic anti-cancer effects with 5-Fu. PEGylated niosomes, which are prepared from biocompatible nonionic surfactant of Spans 60 and cholesterol, and modified with PEG-SA. Pae-PEG-NISVs were evaluatedin vitroandin vivo. The cytotoxicity of Pae-PEG-NISVs was investigated against HepG2 cells. Fluorescence microscope was used to detect the apoptotic morphological changes. Growth inhibition assays were carried out to investigate whether Pae-PEG-NISVs could enhance the antiproliferative effects of Pae co-treated with 5-FU on HepG2 cells. The optimized Pae-PEG-NISVs had mean diameters of approximately 166 nm and entrapment efficiency (EE) of 61.8%. Furthermore, thein vitrorelease study of Paeonol from PEGylated niosomes exhibited a relatively prolonged release profile for 12 h. Pharmacokinetic studies in rats after i.v. injection showed that Pae-PEG-NISVs had increased elimination half-lives (t1/2, 87.5 versus 17.0 min) and increased area under the concentration–time curve (AUC0-t, 38.0 versus 19.48 μg/ml*min) compared to Paeonol solution. Formulated Paeonol had superior cytotoxicity versus the free drug with IC50values of 22.47 and 85.16 μg/mL at 24 h on HepG2 cells, respectively, and we found that low concentration of Pae-PEG-NISVs and 5-Fu in conjunction had obviously synergistic effect. Our results indicate that the PEG-NISVs system has the potential to serve as an efficient carrier for Paeonol by effectively solubilizing, stabilizing and delivering the drug to the cancer cells. [ABSTRACT FROM PUBLISHER]